AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting
May 20, 2021
Hangzhou, China/New York May 19, 2021 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually on June 4-8, 2021. Details on the abstract and a corresponding poster presentation are shown below.
Abstract Number: 9066
Investigator: Dr. Caicun Zhou (Shanghai Pulmonary Hospital, Tongji University, Shanghai, China)
Session Type: Poster
Poster Title: Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer (NSCLC)
Session Title: Lung Cancer—Non-Small Cell Metastatic
Date and Time: June 4, 2021, 9:00 AM – 12:00 PM (EDT)
More information about the ASCO 2021 virtual meeting may be accessed here. The data cutoff date for the released abstract was Jan 15, 2021 and the cutoff date for the poster to be presented at the ASCO 2021 meeting was April 8, 2021.
AnHeart Therapeutics, Co., Ltd. (“AnHeart”) is a clinical stage biopharmaceutical company developing novel oncology therapies. AnHeart is headquartered in Hangzhou, China with offices in Beijing, Shanghai and has a subsidiary AnHeart Therapeutics Inc. in New York. Led by a management team with a successful track record of clinical development, AnHeart is developing three clinical stage oncology programs globally.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements contained in this presentation include, but are not limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates and our research and development programs; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our product candidates and market adoption of our product candidates by physicians and patients; and (v) the timing or likelihood of regulatory filings and approvals. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. This Presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration or regulatory agencies in other countries. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.
Akira Jing Liu, MD
Senior Director of Business Development and Licensing
(86) 137-0181-9470 (c)
Investor Relations Contact:
LifeSci Advisors, LLC